Page last updated: 2024-12-06

zabicipril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zabicipril: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71262
CHEMBL ID3989608
SCHEMBL ID636681
MeSH IDM0180091

Synonyms (16)

Synonym
zabicipril
83059-56-7
(2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3-azabicyclo[2.2.2]octane-2-carboxylic acid
A842490
(2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxidanylidene-4-phenyl-butan-2-yl]amino]propanoyl]-3-azabicyclo[2.2.2]octane-2-carboxylic acid
(3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-2-azabicyclo(2.2.2)octane-3-carboxylic acid, 1-ethyl ester
unii-475035ss4c
475035ss4c ,
zabiciprilum [latin]
zabiciprilum
zabicipril [inn]
zabicipril [who-dd]
SCHEMBL636681
CHEMBL3989608
Q27259001
(3s)-2-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2-azabicyclo[2.2.2]octane-3-carboxylic acid

Research Excerpts

Overview

Zabicipril (S 9650) is a new angiotensin-converting enzyme inhibitor. Hydrolysis in vivo produces the pharmacologically active metabolite zabicipronat (S 10211) Zabiciprin has been observed to increase diuresis, natriuresis and renal plasma flow.

ExcerptReferenceRelevance
"Zabicipril (S 9650) is a new angiotensin-converting enzyme inhibitor whose hydrolysis in vivo produces the pharmacologically active metabolite zabiciprilat (S 10211). "( Enzyme immunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite in human plasma: application to pharmacokinetic studies.
Créminon, C; Ezan, E; Grognet, JM; Lelièvre, E; Morge, X; Piraube, C, 1993
)
1.96
"Zabicipril is a recently introduced angiotensin converting enzyme (ACE) inhibitor, which has been observed in experimental animals to increase diuresis, natriuresis, glomerular filtration rate (GFR) and renal plasma flow (RPF). "( Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men.
Carlier, E; Fiasse, A; Leeman, M; Naeije, R; Opsomer, M, 1993
)
1.95

Pharmacokinetics

ExcerptReferenceRelevance
" These assays are therefore suitable for pharmacokinetic studies and drug monitoring in clinical studies."( Enzyme immunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite in human plasma: application to pharmacokinetic studies.
Créminon, C; Ezan, E; Grognet, JM; Lelièvre, E; Morge, X; Piraube, C, 1993
)
0.52

Dosage Studied

ExcerptRelevanceReference
" The safety, tolerance and dose-response relationship with regard to inhibition of plasma ACE activity were characterised initially in an open, pilot, dose-finding study in 12 subjects and further explored in a double-blind, parallel group, placebo controlled study in another 30 subjects."( Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.
Hughes, DM; Lees, KR; MacDonald, NJ; Reid, JL, 1990
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]